Key Takeaways
- • Ropes & Gray advised Bain Capital Private Equity on leading a $600 million Series B financing for Kailera Therapeutics, marking Bain's inaugural biotech investment and positioning the obesity treatment developer for accelerated clinical development.
- • The financing syndicate includes prominent institutional investors—Adage Capital Management, Canada Pension Plan Investment Board, CPP Investments, Qatar Investment Authority, Royalty Pharma, T. Rowe Price Associates, and Surveyor Capital (Citadel)—demonstrating broad institutional confidence in obesity therapeutics.
- • Capital will fund global Phase 3 clinical trials of KAI-9531, Kailera's lead asset, a dual GLP-1/GIP receptor agonist injectable therapy that has demonstrated encouraging early results in China, positioning the company within a competitive obesity drug landscape.
- • Ropes & Gray deployed a multidisciplinary advisory team spanning private equity, venture capital, intellectual property, life sciences, antitrust, and employment practices, reflecting the complexity of biotech financing at scale.
Summary
Global law firm Ropes & Gray has advised Bain Capital Private Equity on leading a $600 million Series B financing round for Kailera Therapeutics, a Waltham, Massachusetts and San Diego, California-based biotechnology company focused on developing injectable and oral therapies for obesity treatment. This financing marks Bain Capital Private Equity's first investment in the biotech sector and represents a significant capital infusion into the competitive obesity therapeutics market.
The financing syndicate is anchored by Bain Capital Private Equity alongside a diverse group of institutional investors including Adage Capital Management LP, Canada Pension Plan Investment Board (CPP Investments), Invus, Janus Henderson Investors, Perseverance Capital, Qatar Investment Authority (QIA), Royalty Pharma, Surveyor Capital (a Citadel company), and T. Rowe Price Associates. The round is fully funded at closing, indicating strong institutional conviction in Kailera's pipeline and market opportunity.
Proceeds will accelerate development of Kailera's obesity treatment portfolio, with particular focus on funding global Phase 3 clinical trials of KAI-9531, the company's most advanced program. KAI-9531 is an injectable dual GLP-1/GIP receptor agonist that has generated encouraging clinical trial results to date in China, positioning it within the rapidly expanding GLP-1 receptor agonist class that has catalyzed significant market activity in obesity therapeutics.
The Ropes & Gray advisory team was headed by private equity partner Bill Mone, venture capital and emerging companies partner Rajarshi Banerjee, and counsel Michael Connolly. The engagement leveraged specialized expertise across the firm's intellectual property transactions, asset management, antitrust, employment, executive compensation and employee benefits, life sciences, data privacy and cybersecurity, and strategic transactions practices—reflecting the regulatory and operational complexity inherent in biotech financing at institutional scale.
The financing syndicate is anchored by Bain Capital Private Equity alongside a diverse group of institutional investors including Adage Capital Management LP, Canada Pension Plan Investment Board (CPP Investments), Invus, Janus Henderson Investors, Perseverance Capital, Qatar Investment Authority (QIA), Royalty Pharma, Surveyor Capital (a Citadel company), and T. Rowe Price Associates. The round is fully funded at closing, indicating strong institutional conviction in Kailera's pipeline and market opportunity.
Proceeds will accelerate development of Kailera's obesity treatment portfolio, with particular focus on funding global Phase 3 clinical trials of KAI-9531, the company's most advanced program. KAI-9531 is an injectable dual GLP-1/GIP receptor agonist that has generated encouraging clinical trial results to date in China, positioning it within the rapidly expanding GLP-1 receptor agonist class that has catalyzed significant market activity in obesity therapeutics.
The Ropes & Gray advisory team was headed by private equity partner Bill Mone, venture capital and emerging companies partner Rajarshi Banerjee, and counsel Michael Connolly. The engagement leveraged specialized expertise across the firm's intellectual property transactions, asset management, antitrust, employment, executive compensation and employee benefits, life sciences, data privacy and cybersecurity, and strategic transactions practices—reflecting the regulatory and operational complexity inherent in biotech financing at institutional scale.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.